Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company crawled date : 2022 - 04 - 12 save search
Insights on the Liver Disease Treatment Global Market to 2027 - by Treatment Type, Disease Type, End-user and Region
Published: 2022-04-12 (Crawled : 21:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: -4.71%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: 2.3%
H: 0.55%
C: 0.36%
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 0.37%
H: 2.99%
C: 2.61%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.2%
H: 1.83%
C: 1.83%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.26%
H: 0.33%
C: -1.5%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: -0.7%
H: 1.91%
C: 1.63%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
treatment liver disease market
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
Published: 2022-04-12 (Crawled : 21:00) - globenewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
GRTS | $0.7459 0.05% 0.05% 2.4M
|
Health Technology
|
| O: 1.63%
H: 2.0%
C: 0.8%
vaccine designation
Apotex Corp. Launches Generic of Abraxane® in the United States
Published: 2022-04-12 (Crawled : 16:00) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.37%
H: 1.05%
C: 0.43%
abraxane
Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
Published: 2022-04-12 (Crawled : 12:20) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: -3.6%
H: 0.79%
C: -3.74%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.37%
H: 1.05%
C: 0.43%
collaboration designation
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.